De-Risking RNA Therapeutics with High-Resolution Sequencing
Panelists:
Wayne Doyle, PhD
Head of Scientific Platforms & Strategy
Eclipsebio
Tina de los Reyes
Strategic Biopharma Development Specialist
Oxford Nanopore Technologies
- Time:
RNA-based therapeutics demand high-resolution quality control to ensure safety, efficacy, and consistency.
In this GEN webinar, Wayne Doyle will showcase how Eclipsebio’s eMERGE platform leverages nanopore sequencing to directly measure critical quality attributes—including base identity, poly(A) tail length, RNA integrity, and secondary structure within lipid nanoparticles. Learn how integrating sequencing-driven insights across development and manufacturing can reduce risk and strengthen confidence as RNA programs advance toward the clinic. Key takeaways from the webinar are:
- How nanopore sequencing enables high-resolution measurement of critical quality attributes (CQAs), including base identity, poly(A) tail length, and RNA integrity.
- How Eclipsebio’s sequencing-first eMERGE platform integrates nanopore and complementary assays to characterize RNA quality, from sequence fidelity and fragmentation to structural features and impurity profiling.
- How embedding sequencing-driven quality analytics into development and manufacturing workflows strengthens product understanding, improves batch-to-batch consistency, and reduces risk across the RNA therapeutic lifecycle.
A live Q&A session will follow the presentations, offering you a chance to pose questions to our expert panelists.
Produced with support from:
The post De-Risking RNA Therapeutics with High-Resolution Sequencing appeared first on GEN - Genetic Engineering and Biotechnology News.
Apa Reaksi Anda?
Suka
0
Kurang Suka
0
Setuju
0
Tidak Setuju
0
Bagus
0
Berguna
0
Hebat
0
